Litigation Details for Shire Canada Inc. v. Alkem Laboratories, Ltd. (S.D.N.Y. 2011)

« Back to Dashboard

Shire Canada Inc. v. Alkem Laboratories, Ltd. (S.D.N.Y. 2011)

Docket		Date Filed	2011-01-11
Court	District Court, S.D. New York	Date Terminated	2011-11-29
Cause	35:271 Patent Infringement	Assigned To	Paul G. Gardephe
Jury Demand	None	Referred To
Patents	7,465,465
Link to Docket	External link to docket

Details for Shire Canada Inc. v. Alkem Laboratories, Ltd. (S.D.N.Y. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-01-11				External link to document

Shire Canada Inc. v. Alkem Laboratories Ltd., 1:11-cv-00233: Litigation Summary and Patent Analysis

Last updated: August 7, 2026

Shire Canada Inc. v. Alkem Laboratories Ltd., No. 1:11-cv-00233, was a Hatch-Waxman patent case filed in the U.S. District Court for the District of Delaware. The dispute concerned Alkem's abbreviated new drug application for a generic mesalamine product directed to Shire's Lialda delayed-release tablets. The case appears to have ended without a reported trial judgment addressing patent validity or infringement. Its commercial importance was tied to the Lialda formulation patent estate and the timing of generic mesalamine entry.

What drug was involved in Shire Canada v. Alkem?

The litigation concerned Lialda, a delayed-release oral mesalamine product used to induce remission in patients with ulcerative colitis.

Item	Information
Brand	Lialda
Active ingredient	Mesalamine, also called 5-aminosalicylic acid
Dosage form	Delayed-release oral tablets
NDA holder at the relevant time	Shire
Regulatory pathway	Abbreviated New Drug Application litigation under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case number	1:11-cv-00233
Plaintiffs	Shire Canada Inc. and related Shire entities
Defendant	Alkem Laboratories Ltd.
Filing year	2011

Lialda used Shire's MMX multi-matrix delivery technology. The formulation was designed to release mesalamine throughout the colon rather than in the upper gastrointestinal tract. That delivery system, rather than the active ingredient itself, was the principal source of patent protection.

What patents protected Lialda in the Alkem litigation?

The central patent associated with Lialda's delayed-release formulation was U.S. Patent No. 6,773,720, titled "Controlled release oral pharmaceutical composition." The patent covered an oral controlled-release formulation using a hydrophilic matrix, a lipophilic matrix and an enteric coating.

Patent	Subject matter	Relevance to Lialda	Listed expiration
U.S. 6,773,720	Controlled-release oral pharmaceutical composition	Core MMX-style formulation patent	June 2020, subject to any applicable patent-term adjustment
Later Lialda patents	Formulation and manufacturing improvements	Supplementary protection for later products or manufacturing features	Generally later than the '720 patent

The '720 patent was the principal early patent protecting the Lialda product architecture. Mesalamine itself was an established active ingredient and was not protected by a new chemical entity patent for Lialda. The litigation therefore focused on formulation claims, not composition-of-matter claims covering mesalamine.

What was the legal basis of the case?

Alkem's ANDA filing created the statutory basis for a patent-infringement action under 35 U.S.C. § 271(e)(2). The filing of the ANDA was treated as an artificial act of infringement because Alkem sought FDA approval to market a product allegedly covered by Shire's listed patents.

The expected issues were:

1. Whether Alkem's proposed generic product fell within the asserted formulation claims.
2. Whether Alkem's ANDA certification created an infringement controversy before commercial launch.
3. Whether the asserted claims were valid and enforceable.
4. Whether Alkem's proposed product avoided infringement through its formulation design.
5. Whether any Paragraph IV certification was supported by non-infringement, invalidity or unenforceability arguments.

A Hatch-Waxman complaint normally triggers an automatic 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation is resolved earlier or the court orders otherwise.

Was this a Paragraph IV patent challenge?

The case was an ANDA patent action and was consistent with a Paragraph IV challenge to Shire's listed Lialda patents. A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

A Paragraph IV filing creates two commercial effects:

• It permits the brand company to sue before generic launch.
• It can give the first substantially complete ANDA filer 180 days of generic exclusivity if the statutory conditions are satisfied.

The public case record does not establish, without the operative ANDA documents and complete docket filings, the precise certification language used by Alkem for each patent or whether Alkem qualified for first-filer exclusivity.

What was the procedural history?

The case was filed in the District of Delaware in 2011. The record reflects a patent dispute arising from Alkem's ANDA filing rather than a post-launch infringement action. No reported opinion from the case appears to have resolved the merits through a bench trial or summary judgment decision.

Procedural issue	Analysis
Complaint	Filed by Shire against Alkem in the District of Delaware
Trigger	Alkem's ANDA filing for a generic mesalamine product
Primary legal framework	35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355(j)
Claim construction	No widely cited Markman decision is associated with the case
Trial	No reported trial verdict identified
Final merits ruling	No reported invalidity or infringement judgment identified
Disposition	The matter appears to have concluded by docket termination or settlement-related dismissal rather than an adjudicated merits decision

A docket termination without a merits opinion does not establish that the asserted patent was valid, infringed or enforceable. It also does not establish that Alkem's proposed product would have infringed had the case proceeded to trial.

What was the Orange Book status of Lialda?

Lialda's Orange Book protection consisted principally of formulation and delivery-system patents. Mesalamine was an established drug substance, so Lialda did not receive the five-year new chemical entity exclusivity available for a new active moiety.

The relevant regulatory protection was therefore a combination of:

• Any applicable three-year exclusivity for a new clinical investigation supporting approval of a new dosage form or indication.
• Patent protection for the delayed-release formulation.
• Additional patent protection for later formulation or manufacturing improvements.
• Potential pediatric exclusivity, if awarded for an applicable patent or regulatory period.

The core '720 patent expired in 2020, approximately 13 years after Lialda's 2007 FDA approval. The Orange Book listing did not itself determine infringement. It identified patents that the brand company asserted covered the approved product for purposes of ANDA certification.

When did Lialda lose exclusivity?

Lialda's key patent barrier was expected to end with expiration of U.S. Patent No. 6,773,720 in June 2020, subject to any patent-term adjustment. Actual generic entry could occur earlier if a settlement authorized an earlier launch, if an ANDA filer prevailed, or if the relevant patent claims were narrowed or invalidated.

The practical exclusivity timeline was:

Date or period	Event
2007	FDA approval of Lialda
2011	Shire filed the Alkem ANDA litigation
2011-2020	Core formulation patent remained a principal barrier
June 2020	Expected expiration of U.S. Patent No. 6,773,720
After 2020	Generic entry became possible subject to remaining listed patents, regulatory approval and any settlement restrictions

Patent expiration did not automatically authorize launch if other unexpired Orange Book-listed patents remained relevant. It also did not eliminate manufacturing, regulatory or substitution barriers.

What formulations were protected?

The Lialda patent estate protected controlled-release oral formulations rather than mesalamine as a molecule.

The relevant technical elements included:

• An enteric coating that resisted release in the stomach.
• A hydrophilic matrix.
• A lipophilic matrix.
• A controlled-release arrangement intended to distribute mesalamine release in the colon.
• Tablet composition and release characteristics tied to the MMX delivery platform.

The formulation claims created design-around opportunities. An ANDA applicant could seek to avoid infringement by changing the matrix composition, coating parameters, excipient ratios, release profile or manufacturing process. The commercial value of those design-arounds depended on whether the resulting product still satisfied FDA's pharmaceutical equivalence and bioequivalence requirements.

Did the case involve method-of-use patents?

The principal risk in this litigation was formulation-based. Lialda's label covered ulcerative-colitis treatment, but the strongest early patent position was associated with the controlled-release formulation.

Method-of-use patents can create separate infringement exposure where an ANDA label directs use of the drug for a patented indication. For Lialda, any method-of-use claims would have been secondary to the formulation claims in evaluating the product's principal patent barrier. The publicly reported case history does not identify a major adjudicated dispute over a stand-alone method-of-use patent.

What was the likely commercial impact?

Lialda was a branded maintenance and induction therapy in the gastrointestinal market. Generic entry threatened:

• Unit volume transferred from Lialda to generic mesalamine.
• Net price erosion after multiple generic entrants.
• Pharmacy substitution.
• Rebate and formulary pressure.
• Loss of prescriber retention after patent expiry.

The litigation was filed well before the expected expiration of the core formulation patent. That timing was commercially significant because an early settlement could establish a negotiated launch date, preserve some period of brand exclusivity and reduce the risk of an adverse validity or infringement ruling.

A precise revenue estimate for the Alkem case cannot be separated from the broader Lialda patent portfolio without the settlement terms, Alkem's ANDA status, launch date and Shire's product-level sales data.

Was there a settlement agreement?

The case appears to have ended without a published merits opinion. In Hatch-Waxman cases, that procedural pattern commonly reflects a settlement, consent dismissal or another negotiated resolution.

The publicly available case disposition does not establish the principal commercial terms, including:

• Whether Alkem received an authorized-generic license.
• Whether Alkem received a fixed launch date.
• Whether the agreement contained a supply arrangement.
• Whether Shire agreed not to challenge Alkem's ANDA.
• Whether the Federal Trade Commission reviewed or challenged the agreement.
• Whether the agreement gave Alkem a period of exclusive or semi-exclusive entry.

Those terms materially affect the value of the litigation outcome. A dismissal alone cannot be treated as evidence that Alkem was permitted to launch immediately.

How strong was Shire's patent estate?

Shire's estate had meaningful commercial strength because the core Lialda patents were directed to the product's delivery architecture. The estate was weaker than a new chemical entity estate because:

1. Mesalamine was not a newly patented molecule.
2. Formulation claims can be vulnerable to validity attacks involving earlier controlled-release systems.
3. A generic applicant may design around individual formulation limitations.
4. Product-by-process or release-profile limitations can create claim-construction disputes.
5. Patent expiry was finite and publicly identifiable.

Strength factor	Assessment
Active-ingredient protection	Low for Lialda, because mesalamine was established
Formulation protection	Material and commercially relevant
Design-around risk	Moderate
Litigation leverage before 2020	Meaningful
Post-expiration protection	Dependent on later patents and regulatory barriers
Biosimilar exposure	None, because Lialda is a small-molecule drug
Generic exposure	High after expiration or authorized settlement entry

Which companies challenged Lialda patents?

Lialda faced ANDA activity from multiple generic-drug companies over time. Known participants in the broader Lialda patent environment included Alkem and other generic manufacturers seeking approval for mesalamine delayed-release products.

The competitive threat differed by filer:

• A first filer could create a 180-day exclusivity bottleneck.
• A later filer could launch after the first filer's exclusivity period or after patent expiry.
• An authorized generic could accelerate price erosion without relying on an independent ANDA launch.
• A settlement could move the expected launch date forward while preserving patent validity.

The Alkem case should therefore be evaluated as one proceeding within a larger generic-entry campaign, not as a stand-alone test of the entire Lialda patent estate.

Did the litigation involve biosimilar risk?

No. Lialda is a chemically synthesized small-molecule drug, not a biologic. The relevant regulatory pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilar provisions under the Biologics Price Competition and Innovation Act were not applicable.

The competitive risk was generic substitution, not biosimilar interchangeability.

What manufacturing and intellectual-property barriers remained?

Lialda's delivery system created manufacturing barriers separate from patent rights. A generic manufacturer had to reproduce a delayed-release product with acceptable:

• Tablet composition.
• Enteric-coating performance.
• Dissolution profile.
• Stability.
• Content uniformity.
• Bioequivalence.
• Manufacturing scale and quality controls.

A technically viable design-around still required FDA approval. That distinction matters because patent clearance alone did not guarantee approval, and FDA approval alone did not eliminate infringement risk under an unexpired formulation patent.

Key Takeaways

• Shire Canada v. Alkem, No. 1:11-cv-00233, was a District of Delaware Hatch-Waxman case involving a generic version of Lialda, a delayed-release mesalamine product.
• The principal patent issue concerned Lialda's controlled-release formulation, particularly U.S. Patent No. 6,773,720.
• The core patent was expected to expire in June 2020, subject to any patent-term adjustment.
• The case did not produce a widely reported merits ruling on validity or infringement.
• Lialda had no biosimilar risk because mesalamine is a small-molecule drug.
• The commercial threat was generic entry through formulation design-around, Paragraph IV litigation or settlement-authorized launch.
• A docket dismissal or termination does not reveal settlement terms or prove that Alkem's proposed product was non-infringing.
• Lialda's patent strength came from formulation technology, not protection of the mesalamine molecule.

FAQs

Did Alkem launch a generic version of Lialda before the core patent expired?

The case docket alone does not establish an authorized pre-expiration launch date. A launch determination requires the applicable settlement terms, FDA approval status and remaining Orange Book patents.

Was U.S. Patent No. 6,773,720 a composition-of-matter patent?

No. The patent was directed to a controlled-release oral pharmaceutical composition and related formulation technology. It did not provide new chemical entity protection for mesalamine.

Could Alkem avoid infringement by changing the tablet coating?

Potentially, if the modified product no longer satisfied each limitation of the asserted claims. The product would still have to satisfy FDA requirements for delayed release, pharmaceutical equivalence and bioequivalence.

Did Shire obtain a permanent injunction against Alkem?

No reported merits decision from this case establishes a permanent injunction. The action appears to have ended without a reported trial judgment.

Was Lialda protected by pediatric exclusivity?

Any pediatric-exclusivity period would depend on an FDA-issued pediatric extension tied to an applicable patent or regulatory exclusivity period. The cited case record does not establish a separate pediatric extension controlling Alkem's litigation outcome.

References

1. U.S. District Court for the District of Delaware. (2011). Shire Canada Inc. v. Alkem Laboratories Ltd., No. 1:11-cv-00233, docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,773,720, Controlled release oral pharmaceutical composition.

4. Food and Drug Administration. (2023). Abbreviated new drug application regulations and patent certification requirements. 21 C.F.R. §§ 314.94, 314.107.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).